CytoDyn Inc. (CYDY)
OTCMKTS
· Delayed Price · Currency is USD
0.327
+0.028 (9.47%)
Feb 24, 2025, 10:44 AM EST
CytoDyn Employees
CytoDyn had 9 employees as of May 31, 2024. The number of employees decreased by 3 or -25.00% compared to the previous year.
Employees
9
Change (1Y)
-3
Growth (1Y)
-25.00%
Revenue / Employee
n/a
Profits / Employee
-$1,747,889
Market Cap
367.12M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Endo Inc. | 2,931 |
| Elite Pharmaceuticals | 64 |
| Glass House Brands | 413 |
| Northwest Biotherapeutics | 25 |
| SANUWAVE Health | 31 |
| Silence Therapeutics | 109 |
| Longduoduo Company | 49 |
CytoDyn News
- 3 hours ago - CytoDyn Announces Promising Survival Observations in mTNBC Patients Treated with Leronlimab - GlobeNewsWire
- 18 days ago - CytoDyn Announces Findings of Statistically Significant Fibrosis Reversal Across Studies with SMC Laboratories - GlobeNewsWire
- 2 months ago - December 2024 Letter to Shareholders - GlobeNewsWire
- 4 months ago - CytoDyn Phase 2 study of leronlimab cleared by FDA - Seeking Alpha
- 4 months ago - CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial - GlobeNewsWire
- 4 months ago - CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories - GlobeNewsWire
- 5 months ago - CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques - GlobeNewsWire
- 5 months ago - CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial - GlobeNewsWire